Literature DB >> 32841414

Cell polarity (the 'four lines') distinguishes gastric dysplasia from epithelial changes in reactive gastropathy.

Kevin M Waters1, Kevan J Salimian2, Naziheh Assarzadegan2, Danielle Hutchings2, Elias P Makhoul1, Annika L Windon2, Mary T Wong1, Lysandra Voltaggio2, Elizabeth A Montgomery2.   

Abstract

AIMS: Gastric dysplasia is a risk factor for synchronous and subsequent gastric carcinoma. Distinguishing gastric dysplasia from reactive changes is subject to interobserver disagreement and is a frequent reason for expert consultation. We previously used assessment of surface cell polarity (the 'four lines') as a key feature to decrease equivocal diagnoses in Barrett oesophagus. In the current study, we examined for the presence or absence of the four lines in gastric dysplasia and reactive gastropathy.
MATERIALS AND METHODS: The study includes all (n = 91) in-house biopsies with at least gastric dysplasia from the surgical pathology archives of two academic institutions during a 5-year period from 2008 to 2012. A reactive gastropathy group (n = 60) was created for comparison.
RESULTS: The dysplasia/neoplasia group was comprised of 14 biopsies of gastric foveolar-type dysplasia, 59 of intestinal-type dysplasia, 14 with dysplasia in fundic gland polyps, three pyloric gland adenomas and one oxyntic gland adenoma. Loss of surface cell polarity was seen in all 88 dysplasia cases with evaluable surface epithelium. All 57 reactive gastropathy cases with evaluable surface epithelium showed intact surface cell polarity except in focal areas directly adjacent to erosions in 17 cases, where the thin wisp of residual surface mucin could not be appreciated on haematoxylin and eosin.
CONCLUSION: Surface cell polarity (the four lines) was lost in all gastric dysplasia biopsies with evaluable surface epithelium and maintained in all biopsies of reactive gastropathy. Caution should be taken in using this feature adjacent to erosions in reactive gastropathy.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  gastric dysplasia; precursor; reactive gastropathy

Mesh:

Year:  2020        PMID: 32841414      PMCID: PMC9281539          DOI: 10.1111/his.14242

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   7.778


  26 in total

1.  Refined Criteria for Separating Low-grade Dysplasia and Nondysplastic Barrett Esophagus Reduce Equivocal Diagnoses and Improve Prediction of Patient Outcome: A 10-Year Review.

Authors:  Kevin M Waters; Kevan J Salimian; Lysandra Voltaggio; Elizabeth A Montgomery
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

2.  Gastric adenocarcinoma with chief cell differentiation: a proposal for reclassification as oxyntic gland polyp/adenoma.

Authors:  Aatur D Singhi; Audrey J Lazenby; Elizabeth A Montgomery
Journal:  Am J Surg Pathol       Date:  2012-07       Impact factor: 6.394

3.  Gastric high-grade dysplasia can be associated with submucosal invasion: evaluation of its prevalence in a series of 121 endoscopically resected specimens.

Authors:  Urara Sakurai; Gregory Y Lauwers; Michael Vieth; Motoji Sawabe; Tomio Arai; Tatsuya Yoshida; Junko Aida; Kaiyo Takubo
Journal:  Am J Surg Pathol       Date:  2014-11       Impact factor: 6.394

4.  Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019.

Authors:  Pedro Pimentel-Nunes; Diogo Libânio; Ricardo Marcos-Pinto; Miguel Areia; Marcis Leja; Gianluca Esposito; Monica Garrido; Ilze Kikuste; Francis Megraud; Tamara Matysiak-Budnik; Bruno Annibale; Jean-Marc Dumonceau; Rita Barros; Jean-François Fléjou; Fátima Carneiro; Jeanin E van Hooft; Ernst J Kuipers; Mario Dinis-Ribeiro
Journal:  Endoscopy       Date:  2019-03-06       Impact factor: 10.093

5.  AGA Clinical Practice Guidelines on Management of Gastric Intestinal Metaplasia.

Authors:  Samir Gupta; Dan Li; Hashem B El Serag; Perica Davitkov; Osama Altayar; Shahnaz Sultan; Yngve Falck-Ytter; Reem A Mustafa
Journal:  Gastroenterology       Date:  2019-12-06       Impact factor: 22.682

6.  British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma.

Authors:  Matthew Banks; David Graham; Marnix Jansen; Takuji Gotoda; Sergio Coda; Massimiliano di Pietro; Noriya Uedo; Pradeep Bhandari; D Mark Pritchard; Ernst J Kuipers; Manuel Rodriguez-Justo; Marco R Novelli; Krish Ragunath; Neil Shepherd; Mario Dinis-Ribeiro
Journal:  Gut       Date:  2019-07-05       Impact factor: 23.059

7.  Pyloric gland adenoma: a clinico-pathological analysis of 90 cases.

Authors:  M Vieth; R Kushima; F Borchard; M Stolte
Journal:  Virchows Arch       Date:  2003-03-26       Impact factor: 4.064

8.  Gastric dysplasia. A follow-up study.

Authors:  C Di Gregorio; P Morandi; R Fante; C De Gaetani
Journal:  Am J Gastroenterol       Date:  1993-10       Impact factor: 10.864

9.  Gastric adenomas: intestinal-type and gastric-type adenomas differ in the risk of adenocarcinoma and presence of background mucosal pathology.

Authors:  Susan C Abraham; Elizabeth A Montgomery; Vikesh K Singh; John H Yardley; Tsung-Teh Wu
Journal:  Am J Surg Pathol       Date:  2002-10       Impact factor: 6.394

Review 10.  Gastric cancer: overview.

Authors:  Pelayo Correa
Journal:  Gastroenterol Clin North Am       Date:  2013-02-21       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.